cytarabine has been researched along with mk-8776 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Flatten, KS; Hess, AD; Karnitz, LM; Karp, JE; Kaufmann, SH; Koh, BD; Parry, D; Peterson, KL; Schenk, EL; Smith, BD | 1 |
| Carraway, HE; Flatten, KS; Freshwater, T; Gladstone, DE; Gore, SD; Greer, JM; Horowitz, JA; Isaacs, R; Karp, JE; Kaufmann, SH; Levis, MJ; Loechner, S; Mackey, K; McDevitt, MA; Parry, DA; Peterson, K; Pratz, KW; Schneider, P; Showel, MM; Smith, BD; Sorge, C; Thomas, BM | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Bertoli, S; Cartel, M; Cazaux, C; David, L; Delabesse, E; Deshaies, D; Didier, C; Fernandez-Vidal, A; Grgurevic, S; Hoffmann, JS; Larrue, C; Lepage, B; Manenti, S; Prade, N; Récher, C; Sarry, JE | 1 |
| Blackford, AL; Doyle, LA; Gojo, I; Huntoon, CJ; Karnitz, LM; Karp, JE; Kaufmann, SH; Kinders, R; Litzow, M; Morris, L; Patnaik, M; Rosner, GL; Smith, BD; Tibes, R; Wang, L; Webster, JA | 1 |
| Che, F; Gui, C; Huang, J; Wang, C; Zhang, L | 1 |
| Duffield, AS; Hamaker, M; Li, L; Small, D; Wu, M | 1 |
1 review(s) available for cytarabine and mk-8776
| Article | Year |
|---|---|
A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Bayes Theorem; Cytarabine; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Naphthyridines; Neoplasm Recurrence, Local; Odds Ratio; Pyrazoles; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles | 2018 |
4 trial(s) available for cytarabine and mk-8776
| Article | Year |
|---|---|
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Histones; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
CHK1 as a therapeutic target to bypass chemoresistance in AML.
Topics: Checkpoint Kinase 1; Cytarabine; DNA Replication; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Pyrazoles; Pyrimidines | 2016 |
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazoles; Pyrimidines | 2017 |
4 other study(ies) available for cytarabine and mk-8776
| Article | Year |
|---|---|
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cytarabine; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines | 2012 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cytarabine; DNA Repair Enzymes; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Pyrazoles; Pyrimidines; rac1 GTP-Binding Protein; Tandem Repeat Sequences; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |